Treatment algorithm of newly diagnosed AML incorporating novel single-agent and combination therapies. Dotted lines represent therapeutic options of unclear benefit and/or warranting additional research. This algorithm does not encompass the treatment of acute promyelocytic leukemia. CBF-AML, core binding factor acute myeloid leukemia; chemo, chemotherapy; HMA, hypomethylating agent; t-AML, therapy-related acute myeloid leukemia.